{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:39:24Z","timestamp":1791815964618,"version":"4.3.4"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Hepatocellular carcinoma (HCC) accounts for approximately 90% of liver cancer cases. Sorafenib, the first drug to demonstrate survival benefits for advanced HCC, was validated through the SHARP randomized clinical trial (RCT). While RCTs are essential for assessing new therapies, real-world studies provide additional insights into their effectiveness in routine clinical practice. This study aimed to evaluate sorafenib\u2019s real-world effectiveness by analyzing overall survival (OS) and the time to radiological and symptomatic progression. Methods: Data from 368 patients treated with sorafenib at a Brazilian Cancer Center between 2009 and 2020 were retrospectively reviewed. Results: The median OS was 9.6 months, and the time to radiological progression was 5.3 months, similar to the SHARP trial. However, the time to symptomatic progression was shorter (2.3 months) than the SHARP study (4.1 months). In terms of safety, 27.4% of patients presented clinically relevant toxicities, and 24.5% needed to discontinue treatment due to toxicity. Conclusions: Overall, sorafenib demonstrated effectiveness in the studied population, with OS and radiological progression times comparable to SHARP study results. The difference in symptomatic progression may be due to the study\u2019s retrospective nature and limitations.<\/jats:p>","DOI":"10.3390\/curroncol31110500","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:36:39Z","timestamp":1730806599000},"page":"6778-6790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World, Observational, Retrospective Study to Evaluate the Effectiveness and Safety of Treatment with Sorafenib in Patients with Advanced Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-5517","authenticated-orcid":false,"given":"Ang\u00e9lica Richart","family":"Csipak","sequence":"first","affiliation":[{"name":"Oncology, Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, S\u00e3o Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-3618","authenticated-orcid":false,"given":"Leonardo G.","family":"da Fonseca","sequence":"additional","affiliation":[{"name":"Oncology, Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, S\u00e3o Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana Ver\u00f3nica Mendoza","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Comprehensive Center for Precision Oncology C2PO, Center for Translational Research in Oncology, Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, S\u00e3o Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Del Pilar","family":"Estevez-Diz","sequence":"additional","affiliation":[{"name":"Oncology, Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, S\u00e3o Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"ref_1","unstructured":"IARC (2023, September 06). Cancer Fact Sheets: Stomach Cancer. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/39-All-cancers-fact-sheet.pdf."},{"key":"ref_2","unstructured":"IARC (2023, September 06). Cancer Today. Available online: https:\/\/gco.iarc.fr\/today\/online-analysis-table?v=2020&mode=population&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=11&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma: An emphasis on demographic and regional variability","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin. Liver Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"381","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12328-016-0670-7","article-title":"Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma","volume":"9","author":"Moriguchi","year":"2016","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/fon-2020-0758","article-title":"Systemic therapy of advanced hepatocellular carcinoma","volume":"17","author":"Galle","year":"2021","journal-title":"Future Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.3748\/wjg.v24.i36.4152","article-title":"Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and\/or prognostic markers?","volume":"24","author":"Marisi","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_22","unstructured":"FDA (2023, October 05). Real-World Evidence, Available online: https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5604\/01.3001.0012.7909","article-title":"Experience with sorafenib in 3 hospitals in Sao Paulo","volume":"18","author":"Malzyner","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000490378","article-title":"Sorafenib for advanced hepatocellular carcinoma: A real-life experience","volume":"36","author":"Longo","year":"2018","journal-title":"Dig. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/00365521.2016.1166518","article-title":"Sorafenib in the treatment of hepatocellular carcinoma: A multi-centre real-world study","volume":"51","author":"Doyle","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MCG.0000000000001085","article-title":"Sorafenib for treatment of hepatocellular carcinoma: A survival analysis from the South American liver research network","volume":"53","author":"Leathers","year":"2019","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5604\/16652681.1231587","article-title":"The impact of early dermatologic events in the survival of patients with hepatocellular carcinoma treated with sorafenib","volume":"16","author":"Branco","year":"2017","journal-title":"Ann. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40290-022-00456-6","article-title":"Real-world evidence: A primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharm. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/500\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:26:28Z","timestamp":1760113588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["curroncol31110500"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31110500","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}